Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

Similar articles for PubMed (Select 24444539)

1.

Pioglitazone use and the risk of bladder cancer.

Kuo HW, Tiao MM, Ho SC, Yang CY.

Kaohsiung J Med Sci. 2014 Feb;30(2):94-7. doi: 10.1016/j.kjms.2013.09.011. Epub 2013 Oct 29.

PMID:
24444539
2.
3.

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.

Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H.

Diabetologia. 2012 Jul;55(7):1953-62. doi: 10.1007/s00125-012-2538-9. Epub 2012 Mar 31.

4.

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.

Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S.

BMJ. 2012 May 30;344:e3645. doi: 10.1136/bmj.e3645.

5.

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

Tseng CH.

Diabetes Care. 2012 Feb;35(2):278-80. doi: 10.2337/dc11-1449. Epub 2011 Dec 30.

6.

Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus.

Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM, Chan KA.

Hepatology. 2012 May;55(5):1462-72. doi: 10.1002/hep.25509.

PMID:
22135104
7.

The association of pioglitazone and urinary tract disease in type 2 diabetic Taiwanese: bladder cancer and chronic kidney disease.

Lee MY, Hsiao PJ, Yang YH, Lin KD, Shin SJ.

PLoS One. 2014 Jan 10;9(1):e85479. doi: 10.1371/journal.pone.0085479. eCollection 2014.

8.

Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.

Jin SM, Song SO, Jung CH, Chang JS, Suh S, Kang SM, Jung I, Park CY, Kim JH, Cho JH, Lee BW.

J Korean Med Sci. 2014 Feb;29(2):238-42. doi: 10.3346/jkms.2014.29.2.238. Epub 2014 Jan 28.

9.

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.

Zhu Z, Shen Z, Lu Y, Zhong S, Xu C.

Diabetes Res Clin Pract. 2012 Oct;98(1):159-63. doi: 10.1016/j.diabres.2012.05.006. Epub 2012 Jun 16.

PMID:
22705039
10.

Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.

He S, Tang YH, Zhao G, Yang X, Wang D, Zhang Y.

Tumour Biol. 2014 Mar;35(3):2095-102. doi: 10.1007/s13277-013-1278-x. Epub 2013 Oct 4.

PMID:
24092576
11.

Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S.

Clin Drug Investig. 2013 Sep;33(9):621-31. doi: 10.1007/s40261-013-0106-9.

12.

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.

Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH.

Diabet Med. 2013 Sep;30(9):1026-32. doi: 10.1111/dme.12144. Review.

PMID:
23350856
13.

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL.

Diabetes Care. 2011 Apr;34(4):916-22. doi: 10.2337/dc10-1068.

14.

Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.

Lewis JD, Habel L, Quesenberry C, Mamtani R, Peng T, Bilker WB, Hedderson M, Nessel L, Vaughn DJ, Strom BL, Ferrara A.

Pharmacoepidemiol Drug Saf. 2014 Jun;23(6):636-45. doi: 10.1002/pds.3619. Epub 2014 Apr 25.

PMID:
24764283
15.

Pioglitazone and bladder cancer: a propensity score matched cohort study.

Wei L, MacDonald TM, Mackenzie IS.

Br J Clin Pharmacol. 2013 Jan;75(1):254-9. doi: 10.1111/j.1365-2125.2012.04325.x.

16.

Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.

Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K, Tatsuoka H, Matsuoka A, Wada Y, Ikeda H, Fujikawa J, Koshiyama H.

Diabetes Res Clin Pract. 2013 Feb;99(2):e21-3. doi: 10.1016/j.diabres.2012.11.013. Epub 2012 Dec 7.

PMID:
23228390
17.
18.

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD.

J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9.

19.

Use of thiazolidinediones and risk of bladder cancer: disease or drugs?

Bazelier MT, de Vries F, Vestergaard P, Leufkens HG, De Bruin ML.

Curr Drug Saf. 2013 Nov;8(5):364-70.

PMID:
24215315
20.

Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?

Tseng CH.

J Formos Med Assoc. 2012 Mar;111(3):123-31. doi: 10.1016/j.jfma.2011.10.003. Epub 2012 Feb 15. Review.

PMID:
22423665
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk